ASCO Annual Meeting: Sarcoma | Conference

CancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.

Pimitespib significantly improved progression-free survival while prolonging overall survival compared with placebo to treat patients with advanced gastrointestinal stromal tumor.

Patients with advanced synovial sarcoma who received treatment with catequentinib experienced improved disease control and progression-free survival compared with dacarbazine.

Results of the phase 2 SPEARHEAD-1 trial were presented at the 2021 ASCO Annual Meeting, with a high overall response rate reported with afamitresgene autoleucel in advanced synovial sarcoma or myxoid/round cell liposarcoma.

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.

Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.

Busulfan/melphalan high-dose chemotherapy consolidation is associated with better survival vs VAI among patients with localized high-risk Ewing sarcoma.

Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.